

SCHEDULE OF INVESTMENTS

March 31, 2019

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS[†] - 99.5%					
BIOTECHNOLOGY - 71.6%					
Amgen, Inc.	82,098	\$ 15,596,978			
Gilead Sciences, Inc.	201,679	13,111,152			
Celgene Corp.*	125,977	11,884,670			
Regeneron Pharmaceuticals, Inc.*	23,577	9,681,188			
Vertex Pharmaceuticals, Inc.*	52,587	9,673,379			
Illumina, Inc.*	30,965	9,620,516			
Biogen, Inc.*	35,227	8,326,958			
Alexion Pharmaceuticals, Inc.*	57,892	7,825,840			
Incyte Corp.*	72,204	6,210,266			
BioMarin Pharmaceutical, Inc.*	61,119	5,429,201			
Seattle Genetics, Inc.*	65,828	4,821,243			
Ionis Pharmaceuticals, Inc.*	58,598	4,756,400			
Alnylam Pharmaceuticals, Inc.*	48,540	4,536,063			
Exact Sciences Corp.*	49,810	4,314,542			
Bluebird Bio, Inc.* ¹	26,440	4,159,805			
Sage Therapeutics, Inc.*	25,786	4,101,263			
Exelixis, Inc.*	155,418	3,698,948			
Amarin Corporation plc ADR* ¹	157,880	3,277,589			
United Therapeutics Corp.*	27,506	3,228,379			
Spark Therapeutics, Inc.*	26,506	3,018,503			
FibroGen, Inc.*	55,457	3,014,088			
Ultragenyx Pharmaceutical, Inc.*	40,850	2,833,356			
ACADIA Pharmaceuticals, Inc.*	102,919	2,763,375			
Immunomedics, Inc.*	142,066	2,729,088			
Intercept Pharmaceuticals, Inc.*	22,729	2,542,466			
Ligand Pharmaceuticals, Inc. — Class B* ¹	18,021	2,265,420			
PTC Therapeutics, Inc.*	57,160	2,151,502			
Myriad Genetics, Inc.*	62,803	2,085,060			
REGENXBIO, Inc.*	36,340	2,082,645			
Medicines Co.* ¹	74,046	2,069,586			
Spectrum Pharmaceuticals, Inc.*	145,472	1,555,096			
Total Biotechnology		<u>163,364,565</u>			
PHARMACEUTICALS - 24.5%					
AbbVie, Inc.	194,173	15,648,402			
Sarepta Therapeutics, Inc.* ¹	34,498	4,111,817			
Neurocrine Biosciences, Inc.*	45,899	4,043,702			
PRA Health Sciences, Inc.*	35,930	3,962,720			
Jazz Pharmaceuticals plc*	25,485	3,643,081			
Array BioPharma, Inc.*	134,963	3,290,398			
Nektar Therapeutics*	96,851	3,254,194			
Alkermes plc*	85,610	3,123,909			
Agios Pharmaceuticals, Inc.*	43,188	2,912,599			
Global Blood Therapeutics, Inc.*	46,173	2,443,937			
Portola Pharmaceuticals, Inc.* ¹	64,060	2,222,882			
Heron Therapeutics, Inc.*	83,880	2,050,027			
Supernus Pharmaceuticals, Inc.*	53,315	1,868,157			
Madrigal Pharmaceuticals, Inc.* ¹	14,540	1,821,280			
Clovis Oncology, Inc.*	62,960	1,562,667			
Total Pharmaceuticals		<u>55,959,772</u>			
			HEALTHCARE-PRODUCTS - 1.8%		
			Bio-Techne Corp.	19,908	\$ 3,952,733
			HEALTHCARE-SERVICES - 1.6%		
			Syneos Health, Inc.*	71,540	3,702,910
			Total Common Stocks		
			(Cost \$106,577,433)		
			<u>226,979,980</u>		
			RIGHTS^{†††} - 0.0%		
			Clinical Data, Inc.* ²	24,000	—
			Total Rights		
			(Cost \$—)		
			<u>—</u>		
			FACE AMOUNT		
			<hr/>		
			REPURCHASE AGREEMENTS^{†††,3} - 0.6%		
			JPMorgan Chase & Co.		
			issued 03/29/19 at 2.55%		
			due 04/01/19	\$ 889,370	889,370
			Bank of America Merrill Lynch		
			issued 03/29/19 at 2.55%		
			due 04/01/19	222,343	222,343
			Barclays Capital		
			issued 03/29/19 at 2.40%		
			due 04/01/19	199,147	199,147
			Total Repurchase Agreements		
			(Cost \$1,310,860)		
			<u>1,310,860</u>		
			SHARES		
			<hr/>		
			SECURITIES LENDING COLLATERAL^{†,4} - 3.9%		
			Money Market Fund		
			First American Government		
			Obligations Fund — Class Z, 2.32% ⁵	8,986,751	8,986,751
			Total Securities Lending Collateral		
			(Cost \$8,986,751)		
			<u>8,986,751</u>		
			Total Investments - 104.0%		
			(Cost \$116,875,044)		
			<u>\$ 237,277,591</u>		
			Other Assets & Liabilities, net - (4.0)%		
			<u>(9,172,561)</u>		
			Total Net Assets - 100.0%		
			<u>\$ 228,105,030</u>		

BIOTECHNOLOGY FUND

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

¹ All or a portion of this security is on loan at March 31, 2019.

² Security was fair valued by the Valuation Committee at March 31, 2019. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

³ Repurchase Agreements.

⁴ Securities lending collateral.

⁵ Rate indicated is the 7-day yield as of March 31, 2019.

ADR — American Depositary Receipt

plc — Public Limited Company